AstraZeneca Pharma India CFO Bhavana Agrawal resigns, moves to regional role

Cfo ResignedManagement Changes View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹8068.00

prior close

₹8080.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.2%+0.5% vs market

Pharmaceuticals peers, median of 165sector-1.6%+0.9% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.4

15m

-0.4

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7-1.2+0.5-1.6+0.9

Next day

-2.3-1.9-0.4-2.5+0.1

-0.7-1.4+0.8-2.5+1.8

+0.5-0.1+0.7-1.4+1.9

+0.1-1.4+1.5-2.5+2.6

+1.6-1.0+2.6-1.9+3.5

+0.4-0.4+0.8-2.1+2.5

15d

-2.1+3.2-5.3-0.3-1.8

-10.6+4.4-15.0-1.1-9.5

-16.7+4.6-21.3+1.1-17.8

-25.4-3.6-21.8-6.4-19.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ms. Bhavana Agrawal, Executive Director and CFO of AstraZeneca Pharma India, has resigned as CFO effective close of business on August 31, 2026. Reason given is her appointment to a regional role within the AstraZeneca Group. No replacement CFO has been announced yet. She holds NIL shares in the company.

Likely market impact

CFO transition tied to internal group rotation, not a red flag. Watch for naming of replacement and continuity in financial reporting.